David Vaczek

Most Recent Articles by David Vaczek

In Focus: Making the case for biosimilars

In Focus: Making the case for biosimilars

By

Sandoz will need to put across the biosimilar concept to doctors as it challenges Neupogen and Teva's Granix

MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics

MM&M's 5 minutes with: Mark Rothera, chief commercial officer, PTC Therapeutics

By

The biotech exec speaks about the global launch of his firm's lead product, Duchenne drug Translarna.

Sandoz gets ready to make the biosimilar case with oncologists

Sandoz gets ready to make the biosimilar case with oncologists

By

Novartis's Sandoz will kickstart its marketing plans as it awaits FDA's decision to approve the first biosimilar in the US.

Five things for pharma marketers to  know: Thursday, January 8

Five things for pharma marketers to know: Thursday, January 8

By By By

Sandoz received FDA biosimilar nod; new technique yields 25 antibiotics; Novartis sends two COPD drugs for FDA review.

Orphan-focused shop Siren Interactive scooped up by life-sci services firm

Orphan-focused shop Siren Interactive scooped up by life-sci services firm

By

Siren, one of the most experienced agencies in the rare-disease space, will add its patient-outreach expertise to new owner Dohmen's patient-care model.

More Articles by David Vaczek